The tweet was deleted by the author.
But we saved everything 🙂.
Invivyd announced the presentation of VMS063, a monoclonal antibody candidate aimed at the treatment and prevention of measles, at IDWeek 2026.
The potential best-in-class candidate demonstrates the companys ongoing efforts to develop advanced therapies targeting infectious diseases.
View post on X Loading...
Invivyd previously announced positive topline results for VYD2311 in a Phase 3 COVID-19 study. The LIBERTY trial showed VYD2311 to be safer and more tolerable than mRNA COVID-19 vaccines. The company has since pursued regulatory submissions for the candidate.